Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 11.2% from a year ago
Common stock stood at $14.67K at the end of Q1 FY2026, up 11.2% from a year earlier and up 2.6% from the prior quarter. Over 3 fiscal years it compounded at +3.6% a year.
Context
- Common stock amounted to 0.1% of total assets at the end of Q1 FY2026, down 0.3 pp from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +11.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 14.3K USD
- Year-over-year change
- +8.7%
- 4-year CAGR
- +2.1%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.3K | +8.7% |
| FY2024 | 2024-12-31 | 13.15K | +2.4% |
| FY2023 | 2023-12-31 | 12.85K | +0.0% |
| FY2022 | 2022-12-31 | 12.85K | -2.3% |
| FY2021 | 2021-12-31 | 13.15K | — |
Common Stock vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +11.2% is the 6th highest of 9, against a peer median of +42.4%.
- Common stock amounts to 0.1% of total assets for GLSI, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $385K USD | +44.7% | -51.3% | 0.2% | |
| Mar 2026 | $90K USD | +45.2% | +45.9% | 0.2% | |
| Mar 2026 | $63.58K USD | +45.6% | +135.7% | 0.2% | |
| Mar 2026 | $14.67K USD | +11.2% | +3.6% | 0.1% | |
IRDOpus Genetics, Inc. | Mar 2026 | $7K USD | +40.0% | +51.8% | 0.0% |
| Mar 2026 | $5.31K USD | +90.0% | +56.0% | 0.0% | |
| Mar 2026 | $1K USD | +0.0% | — | 0.0% | |
| Mar 2026 | $1K USD | +0.0% | +0.0% | 0.0% | |
| Mar 2026 | CA$0 CAD | -100.0% | — | 0.0% | |
| Peer median (excluding GLSI) | — | +42.4% | +48.8% | 0.0% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.